Key points New evidence has led to a change in the way that some patients with amyotrophic lateral sclerosis (ALS) are classified and treated. Based on the findings of a landmark trial,[1][1] the drug ...

Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with ...

Amyotrophic lateral sclerosis (ALS), formerly known as Lou Gehrig’s disease, is a progressive and fatal neurodegenerative ...

The ALS Association's Walk to Defeat ALS in Springfield will raise money for research into the neurodegenerative disease.

Globally recognized figures like Muhammad Ali and Michael J. Fox have long suffered from Parkinson's disease. The disease ...

An American man dying of heart failure received the heart of a Canadian man with ALS who chose a medically assisted death in ...

A new trial assessing the ability of COYA 302 to slow the progression of ALS will enroll up to 120 patients at sites in the U ...

Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active progressive MS (primary progressive and ...

DAYTON, Ohio ( WDTN) – Hundreds of people walked two miles at Day Air Ball Park to support people living with ALS ...

In a now-completed clinical trial, the stem cell therapy Neuronata-R was found to benefit ALS patients with slower disease ...

Last month, a spark was ignited within the scientific community as a team of researchers demonstrated a scientific method for ...